UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Blood, 2020-05, Vol.135 (20), p.1739-1749

2020

Volltextzugriff (PDF)

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

Haematologica (Roma), 2018-09, Vol.103 (9), p.e404-e407

2018

Volltextzugriff (PDF)

Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients

Transplantation and cellular therapy, 2021-11, Vol.27 (11), p.938.e1-938.e6

2021

Volltextzugriff (PDF)

Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration

Haematologica (Roma), 2023-12, Vol.108 (12), p.3321-3332

2023

Volltextzugriff (PDF)

2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management

American journal of hematology, 2021-11, Vol.96 (11), p.1532-1538

2021

Volltextzugriff (PDF)

Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients

Haematologica (Roma), 2018-10, Vol.103 (10), p.1662-1668

2018

Volltextzugriff (PDF)

2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management

American journal of hematology, 2024-05, Vol.99 (5), p.938-945

2024

Volltextzugriff (PDF)

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents

Blood advances, 2019-12, Vol.3 (23), p.4043-4049

2019

Volltextzugriff (PDF)

Use of monoclonal antibody therapy in hematologic patients with mild‐to‐moderate COVID‐19: A retrospective single‐center experience

Cancer medicine (Malden, MA), 2023-05, Vol.12 (10), p.11248-11253

2023

Volltextzugriff (PDF)

Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes

Blood cancer journal (New York), 2021-07, Vol.11 (7), p.125-125, Article 125

2021

Volltextzugriff (PDF)

Ponatinib, asciminib and inotuzumab ozogamicin: A novel drug combination in acute lymphoblastic leukemia

Leukemia research, 2023-06, Vol.129, p.107299-107299, Article 107299

2023

Volltextzugriff (PDF)

Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

American journal of hematology, 2019-10, Vol.94 (10), p.E253-E255

2019

Volltextzugriff (PDF)

Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer

British journal of haematology, 2024-07, Vol.205 (1), p.158-165

2024

Volltextzugriff (PDF)

Refractory primary autoimmune myelofibrosis treated with ruxolitinib

American journal of hematology, 2021-08, Vol.96 (8), p.E283-E285

2021

Volltextzugriff (PDF)

Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia

British journal of haematology, 2024-08, Vol.205 (2), p.711-715

2024

Volltextzugriff (PDF)

State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia

Leukemia, 2024-04, Vol.38 (4), p.769-780

2024

Volltextzugriff (PDF)

Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings

Bone marrow transplantation (Basingstoke), 2024-08

2024

Volltextzugriff (PDF)

Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib

Bone marrow transplantation (Basingstoke), 2022-05, Vol.57 (5), p.830-833

2022

Volltextzugriff (PDF)

A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement

Bone marrow transplantation (Basingstoke), 2023-09, Vol.58 (9), p.991-999

2023

Volltextzugriff (PDF)

Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia

American journal of hematology, 2020-10, Vol.95 (10), p.1193-1199

2020

Volltextzugriff (PDF)

Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT

Leukemia research, 2021-05, Vol.104, p.106579, Article 106579

2021

Volltextzugriff (PDF)

Donor-specific HLA antibodies associate with chronic graft-versus-host disease in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide

Bone marrow transplantation (Basingstoke), 2022-01, Vol.57 (1), p.134-136

2022

Volltextzugriff (PDF)

Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia

British journal of haematology, 2022-03, Vol.196 (6), p.e71-e74

2022

Volltextzugriff (PDF)

Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002

Bone marrow transplantation (Basingstoke), 2023-12, Vol.58 (12), p.1416-1418

2023

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Aktive Filter

ThemaHematology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(66)
Dissertationen
(1)

Sprache

Englisch
(67)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(65)
Science & Technology
(65)
Humans
(44)
Transplantation
(35)
Immunology
(29)
Oncology
(19)
Adult
(18)
Middle Aged
(17)
Retrospective Studies
(16)
Hematopoietic Stem Cell Transplantation
(14)
Acute Lymphoblastic Leukemia
(11)
Female
(11)
Hematopoietic Stem Cell Transplantation - Adverse Effects
(11)
Male
(11)
Biophysics
(10)
Hematopoietic Stem Cells
(10)
Stem Cell Transplantation
(10)
Graft Vs Host Disease - Prevention & Control
(9)
Aged
(8)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients

Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration

2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management

Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients

2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents

Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status

Use of monoclonal antibody therapy in hematologic patients with mild‐to‐moderate COVID‐19: A retrospective single‐center experience

Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes

Ponatinib, asciminib and inotuzumab ozogamicin: A novel drug combination in acute lymphoblastic leukemia

Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer

Refractory primary autoimmune myelofibrosis treated with ruxolitinib

Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia

State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia

Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings

Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib

A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement

Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia

Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT

Donor-specific HLA antibodies associate with chronic graft-versus-host disease in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide

Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia

Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002

Aktive Filter

Suchergebnisse filtern